Xbrane Biopharma AB Balance Sheet

Financials in millions SEK. Fiscal year is January - December.

Millions SEK. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	49.5	86.59	124.33	65.4	193.99	295.18
Cash & Short-Term Investments	49.5	86.59	124.33	65.4	193.99	295.18
Cash Growth	744.37%	-30.36%	90.10%	-66.29%	-34.28%	21.40%
Accounts Receivable	13.65	6.74	16.85	-	1.34	-
Other Receivables	8.86	5.56	16.97	34.21	46.12	50.25
Total Trade Receivables	22.51	12.3	33.83	34.21	47.46	50.25
Inventory	175.18	194.27	246.9	106.86	50.26	-
Other Current Assets	74.59	81.97	200.84	255.22	221.81	215.58
Total Current Assets	321.77	375.13	605.9	461.69	513.52	561.01
Net Property, Plant & Equipment	6.02	0.04	23.86	88.2	71.05	73.8
Other Intangible Assets	314.82	296.46	167.69	99.67	102	49.67
Other Long-Term Assets	-	-	41.04	3.95	3.95	3.95
Total Assets	642.61	671.62	842.43	653.51	690.52	688.43
Accounts Payable	26.34	8.96	242.57	30.97	23.3	41.39
Accrued Expenses	11.86	36.19	188.45	216.3	200.24	159.36
Current Portion of Long-Term Debt	57.77	-	82.5	62.5	-	-
Current Portion of Leases	2.97	-	13.27	13.37	9.16	7.91
Other Current Liabilities	1.84	7.52	11.16	3.42	3.87	11.01
Total Current Liabilities	100.79	52.66	537.94	326.56	236.57	219.67
Long-Term Debt	-	58.31	66.37	112.9	-	-
Long-Term Leases	2.97	-	29.58	42.71	29.06	36.48
Other Long-Term Liabilities	-	-	-	0.01	-	0.54
Total Long-Term Liabilities	2.97	58.31	95.95	155.62	29.06	37.02
Total Liabilities	103.76	110.97	633.89	482.17	265.63	256.69
Common Stock	2.06	2.06	343.5	6.68	6.17	5.61
Additional Paid-in Capital	1,389	1,386	1,395	1,429	1,294	1,134
Accumulated Other Comprehensive Income	10.14	10.11	10.23	10.12	10.32	5.17
Retained Earnings	-862.1	-837.61	-1,540	-1,274	-885.83	-713.31
Shareholders' Equity	538.85	560.65	208.54	171.34	424.89	431.74
Total Liabilities & Equity	642.61	671.62	842.43	653.51	690.52	688.43
Total Debt	63.71	58.31	191.72	231.48	38.22	44.38
Net Cash (Debt)	-14.22	28.28	-67.39	-166.08	155.77	250.8
Net Cash Growth	-	-	-	-	-37.89%	5.88%
Net Cash Per Share	-0.02	1.72	-4.10	-35.06	761.51	1328.77
Book Value	538.85	560.65	208.54	171.34	424.89	431.74
Book Value Per Share	0.70	34.11	12.69	36.17	2077.09	2287.41
Tangible Book Value	224.03	264.19	40.85	71.67	322.89	382.07
Tangible Book Value Per Share	0.29	16.08	2.49	15.13	1578.48	2024.25